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Abstract
A RANDOMIZED TRIAL OF BILEVEL POSITIVE AIRWAY PRESSURE
DEVICE AND HIGH FLOW OXYGEN FOR PERSISTENT DYSPNEA IN
ADVANCED CANCER PATIENTS
Publication No.________*
David Hui, BSc, MSc, MD, FRCPC
Supervisory Professor: Eduardo Bruera, MD

Background: Dyspnea is a common and distressing symptom among
patients with advanced cancer. The role of bilevel positive airway pressure
(BIPAP) and Vapotherm in the relief of dyspnea have not been well defined.
We aimed to determine and to compare the efficacy of BIPAP and
VapoTherm for cancer related dyspnea.
Methods: In this randomized, open-label, crossover study, we randomly
assigned advanced cancer patients with persistent dyspnea ≥3/10 to either
Vapotherm for 2 hours followed by BiPAP for 2 hours, or BiPAP followed by
Vaptherm. A variable washout period was instituted between interventions.
The primary end point was change in numeric rating scale before and after
each intervention. We planned to enroll 50 patients in total.
Results: Among the 803 patients screened over the last 8 months, 62 (26%)
were eligible, and 16 (2%) were enrolled so far. Five patients completed the
entire study successfully, 4 discontinued the study prematurely due to
prolonged relief of dyspnea, and 7 dropped out for various reasons, including
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inability to tolerate BIPAP (N=3), anxiety (N=2), fatigue (N=1) and pain
requiring opioids (N=1).

The median baseline numeric rating score for

dyspnea was 7/10 (interquartile range (IQR) 5-8), and the median baseline
Borg score was 4/10 (3-7).

Interim analysis revealed that BIPAP was

associated with a median change in numeric rating score of -3 (N=10, IQR
-6.3 to -1, p=0.007) and modified Borg score of -1 (N=10, IQR -3 to 0.3,
p=0.058), while Vapotherm was associated with a median change in numeric
rating score of -2 (N=9, IQR -3 to -1, p=0.011) and modified Borg score of
-2.5 (N=8, IQR -5.5 to -0.1, p=0.051).

Among the 5 individuals who

completed the entire study, 2 preferred Vapotherm, 2 favored BIPAP, and 1
liked both.

The respiratory rate decreased and the oxygen saturation

improved with both interventions. No significant toxicities were observed.
Conclusions: We were successfully able to enroll patients onto this clinic
trial. Our preliminary results suggest that BIPAP and Vapotherm are highly
efficacious in providing relief for patients with persistent refractory dyspnea.
A direct comparison of the two interventions will be done upon study
completion. Further research is necessary to confirm our findings.
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Chapter 1. Introduction
A. Background
Dyspnea is a subjective awareness of difficulty breathing, which may be
associated with the distressing sensation of suffocation. It is one of the
most common and most feared symptoms among cancer patients,
occurring in approximately 20-40% of patients at the time of diagnosis of
advanced disease (1, 2), and increases up to 50-70% in the last 6 weeks
of life (3).

Dyspnea has also been shown to be an important prognostic

factor for patients with advanced cancer (4, 5).

The pathophysiology of dyspnea is shown in Figure 1 (6). Causes of
dyspnea can be classified as cancer-related, treatment-related and
psychological factors.

Progressive disease may result in parenchymal

metastasis, lymphagitic carcinomatosis, airway obstruction, atelectasis,
and/or pleural effusion causing difficulty breathing.

Complications of

cancer, including thromboembolism, pneumonia, sepsis and anemia of
chronic disease may also contribute to the sensation of breathlessness.
Cancer patients also tend to have poor respiratory reserve because of
chronic obstructive pulmonary disease (COPD) and/or prior lung
resections, predisposing them to the development of respiratory
symptoms.

In advanced cancer patients with significant cachexia,

dyspnea may also be related to loss of respiratory muscles, an under-
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recognized etiology (6). In a small proportion of patients, no identifiable
etiologic factors can be found.

Current management of dyspnea involves treatment of any reversible
causes and supportive measures to minimize the sensation of dyspnea.
Relief of dyspnea can be achieved by a number of pharmacologic and
non-pharmacologic measures. Common medications for dyspnea include
opioids, bronchodilators, corticosteroids and benzodiazepines.

Opioids

had proven palliative benefit for dyspnea. In a cross over study with 10
cancer patients, Bruera et al. showed that subcutaneous morphine was
more effective at relieving dyspnea compared to placebo 60 minutes after
drug administration (7).

A systemic review suggested that oral and

parenteral, but not nebulized, opioids as effective in managing dyspnea
(8). However, the potential benefit with opioids is limited by its toxicity
profile, particularly sedation and opioid induced neurotoxicity at higher
doses. Even with high doses of opioids and other supportive measures,
some patients continue to experience severe dyspnea.
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Chemoreceptors
↓ PaO2
↑ PaCO2

Mechanoreceptors
J receptors
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∆ airway, lung,
PA pressure
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Vapotherm)

↑ respiratory muscle use

Bilevel Positive
Airway Pressure
(BIPAP)

Figure 1. Pathophysiology of Dyspnea and Potential Mechanisms of
Action of Supplemental Oxygen and BIPAP. The sensory cortex
receives afferent input from mechanoreceptors in airways and chest wall,
stretch and irritant receptors in lungs, chemoreceptors in brainstem, and
other signals from the motor cortex, generating the sensation of
breathlessness. Supplemental oxygen can improve the arterial oxygen
level, reducing the level of chemoreceptor activation, and thus the
sensation of dyspnea. BIPAP not only improves oxygenation, but also
exerts a mechanical effect on the airways and chest wall, which in the
process improves ventilation, work of breathing, and potentially dyspnea.
Non-pharmacologic measures such as supplemental oxygen has been
shown to be beneficial for patients with hypoxemia, although its role in
dyspneic patients who are not hypoxemic remains unresolved (9).

A

prospective, double-blind crossover trial included 14 advanced cancer
patients, and found significant improvements in dyspnea comparing
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oxygen to room air by mask (10). However, a larger study with 33 patients
did not confirm this benefit (11).

The observation that supplemental

oxygen therapy only benefits patients with hypoxemia suggests that
improved oxygenation is only part of the equation for relief of dyspnea. In
recent years, high-flow oxygen delivery devices (VapoTherm) and bilevel
positive airway pressure (BIPAP) have become available for treatment of
acute or chronic respiratory distress, although their potential for relief of
dyspnea in the palliative care population remains to be tested.

VapoTherm is a high flow heat and humidification device that can deliver
oxygen of up to 40 L/min via nasal prongs. Studies on VapoTherm have
so far focused on patients with acute exacerbations of COPD and
congestive heart failure (CHF).

A randomized crossover study of

Vapotherm by nasal prongs versus supplemental oxygen by nonrebreather mask in 14 COPD patients showed equivalent efficacy in terms
of oxygen delivery, but Vapotherm was better tolerated (12).

Another

study of 5 COPD patients compared high flow versus low flow oxygen via
Vapotherm.

The high flow oxygen arm was associated with a trend

towards decreased dyspnea by both numeric rating scale and Borg scale
(13).

BIPAP is a form of non-invasive positive pressure ventilation (NIPPV), and
represents another attractive option for relief of dyspnea using pre-set

4

inspiratory pressure that allows patient to control not only the breathing
rate but also the duration of inspiration (14). It is commonly used for
treatment of acute respiratory failure, including exacerbations of COPD
(15) and CHF (16). Intermittent BIPAP has been studied in the critical
care setting for immunocompromised cancer patients who developed
pneumonia, and has been demonstrated to reduce the need for intubation,
serious complications, and mortality (17).

In the chronic respiratory failure setting, the use of BIPAP has been mostly
limited to patients with neuromascular disorders such as amyotrophic
lateral sclerosis (ALS) (18) and Ducheene muscular dystrophy (19) (Table
1). One study included 20 ALS patients randomized to long term BIPAP
or best supportive care, and found significant survival and satisfaction in
the BIPAP arm (20). A review of 276 patients with chronic respiratory
failure from various causes found that BIPAP was associated with
improved gas exchange and decreased hospitalization (21).
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Table 1. Key Studies of Non-Invasive Positive Pressure Ventilation in
Patients with Advanced Respiratory Failure
Population

NIPPV
Intervention period
settings
ACUTE RESPIRATORY FAILURE IN ADVANCED STAGES OF DISEASE
Benhamou et
Acute on chronic
Prospective
NR
Daily schedule:
al. 1992 (22)
resp. failure
N=30
continuous first 12h, then
(COPD, RLD,
intermittent days and
bronchiectasis),
continuous nights
Total: 11.4 days
elderly 76±8 yrs
Retrospective
NR
Daily schedule:
Freichels et
Acute on chronic
case series N=3
continuous with 1 to 2
al. 1994 (23)
resp. failure
hours off mask
(cancer, COPD,
restrictive). High
PaCO2
Hilbert et al.
Acute resp. failure
Randomized trial IPAP: 15±2
Daily schedule:
2001 (17)
(Immunocompromi
on intermittent
intermittent
cmH2O
sed cancer
BIPAP or supp
45 min up to 3h
EPAP: 6±1
patients)
O2 N=52 (26)
Total: 6±3 days
cmH2O
Levy et al.
2004 (24)

Acute resp. failure
who were DNI

Schettino et
al. 2005 (25)

Acute on chronic
resp failure (COPD,
CHF, advanced
cancer) who were
DNI
CHRONIC RESPIRATORY FAILURE
Legar et al.
Chronic resp.
1994 (21)
failure (COPD,
kyphoscoliosis,
muscular
dystrophy) on
NIPPV
Pinto et al.
Chronic resp.
1995 (20)
failure (ALS)
Lyall et al.
2001 (26)

Chronic resp.
failure (ALS)

REVIEW
Nava et al.
2004 (27)

Review of NIPPV in
cancer patients

Design

Prospective
cohort study
N=114

IPAP: 13±3
cmH2O
EPAP: 5.3±1
cmH2O

Daily schedule:
continuous with
intermittent breaks
Total: 13.2 ±2.4h

Prospective
observational
study
N=131 (40
cancer)

NR

Daily schedule:
continuous. Parameters
recorded +2 h, then q12h
Total: 2 days

Retrospective
case series
N=276

NR

Daytime: 1.5±2h
Nighttime: 9±2h
Total: 6 months

Quasi
randomized trial
N=20 (10)
Prospective case
control N=16

NR

NR

NR

Daytime: as needed
Nighttime: continuous
Total: 6 months

NA

NA

Gas exchange, pH, RR,
dyspnea usually improve
in 1-3 hours

Abbreviations: ALS, amyotrophic lateral sclerosis; DNI, do not intubate;
EPAP, expiratory positive airway pressure; IPAP, inspiratory positive
airway pressure; NA, not applicable; NIPPV, non-invasive positive
pressure ventilation; NR, not reported; RR, respiratory rate

6

B. Study Rationale
Patients with advanced cancer commonly experience dyspnea. Current
treatment

options,

such

as

supplemental

oxygen,

opioids

and

bronchodilators, provide limited relief of this distressing symptom, with
many patients still experiencing persistent dyspnea. One of the limitations
of the current method of supplemental oxygen delivery is that it is
cumbersome and uncomfortable. The maximum rate delivered via nasal
prongs is only 6 L per minute. Patients with higher oxygen requirements
have to wear a non-rebreather mask, which can deliver oxygen of up to 15
L per minute (and up to 21 L per minute with the additional oxygen
delivery by nasal prongs). However, the mask may create a subjective
sensation

of

suffocation

or

claustrophobia

for

patients.

These

impracticalities, coupled with its limited effectiveness in relief of dyspnea,
raises the need for newer modalities of oxygen delivery that can be more
successful in managing dyspnea. Vapotherm and BIPAP represent two
novel therapeutic options for patients with acute and chronic respiratory
failure, although their efficacy in the palliation of dyspnea remains to be
tested.

Vapotherm represents a potentially attractive option for treatment of
dyspnea because it can provide heated, humidified high flow oxygen (up
to 40 L/min) through nasal prongs. The effect of high flow oxygen on the
relief of dyspnea has not been studied in detail, particularly in patients with
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persistent dyspnea despite standard oxygen therapy.

Postulated

mechanisms of how Vapotherm provides relief for dyspnea include (1) the
ability to maintain a high level of PaO2 which has a direct effect the
perception of dyspnea, (2) stimulation of trigeminal nerve, and (3) the
ability to increase positive end expiratory pressure (PEEP).

BIPAP may provide additional benefit to supplemental oxygen therapy
(Figure 1).

BIPAP not only assists ventilation, but also increases

inspiratory flow rate, corrects hypoventilation, resets central respiratory
drive, increases exercise capacity, and unloads respiratory muscles (2729). The last reason is of particular interest for advanced cancer patients
who have dyspnea secondary to loss of respiratory muscles. However,
the potential benefit of BIPAP needs to be balanced against the discomfort
associated with the mask. We believe that some patients would prefer
this modality despite the use of facial/nasal mask if it proved to be able to
effectively improve dyspnea.

A study investigating the effect of Vapotherm and BIPAP on persistent
dyspnea would provide preliminary data regarding the feasibility and
efficacy

of

these

non-invasive

assist

devices

for

alleviation

breathlessness using a crossover, rather than parallel design.

of
A

crossover design is specifically chosen for this study as it allows patients
to determine their overall preference after a trial of both interventions.
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Findings from this feasibility study, such as adherence, cross over period
and outcome measures, could help us to design a larger crossover trial
powered to examine differences in efficacy between these two
interventions. Our long-term goal is to improve the quality of life and care
of patients with advanced cancer who experience the distressing symptom
of dyspnea.

C. Hypotheses
We hypothesize that both intermittent BIPAP and Vapotherm are effective
in the treatment of persistent dyspnea despite standard supplemental
oxygen therapy in advanced cancer patients.

We also postulate that BIPAP is more effective at relieving dyspnea (by
numeric rating scale, Borg Scale, global assessment and washout period)
than high flow oxygen therapy for patients who can tolerate this treatment,
through the added benefits of improving inspiratory flow rate, alveolar
recruitment, chest wall expansion.

We further hypothesize that BIPAP can improve ventilation better than
Vapotherm.

D. Study Objectives
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1. To determine the effects of BIPAP and VapoTherm on the severity of
dyspnea compared to baseline as measured by the Numeric rating
scale and the Borg scale.

2. To compare the effects of BIPAP and VapoTherm on the severity of
dyspnea compared to baseline as measured by the Numeric rating
scale and the Borg scale.

3. To determine the effects of BIPAP and VapoTherm on physiologic
parameters, including heart rate, respiratory rate, blood pressure and
oxygen saturation, and transcutaneous carbon dioxide level.
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Chapter 2. Patients and Methods
A. Study Design
This is an open-label, randomized, crossover study involving VapoTherm
and BIPAP for patients with cancer-related dyspnea (Figure 2). Eligible
patients who agreed to participate were randomized to receive either
BIPAP or VapoTherm for 2 hours in the first treatment phase, followed by
a variable washout period (up to 1 hour) and then either VapoTherm or
BIPAP for 2 hours in the second treatment phase. Because of the nature
of study interventions, blinding was not possible.

This study focused on patients with cancer-related dyspnea, which is
defined as dyspnea predominately related to the underlying malignancy,
with or without other secondary chronic respiratory diseases (e.g. COPD,
asthma, idiopathic pulmonary fibrosis). Potential pathologies may include,
but not limited to, pulmonary parenchymal metastasis, lymphangitic
carcinomatosis, pleural effusion, and significant cachexia with respiratory
muscle weakness.

A crossover design was utilized such that each participant had the
opportunity to try both Vapotherm and BIPAP. At the end of the study,
he/she provided feedback regarding his/her overall preference through a
survey directly comparing the two interventions in terms of dyspnea relief
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and comfort.

This intra-individual comparison would not have been

possible with a parallel design.

Eligible Patients

• Advanced cancer inpatient
• Dyspnea at least 3 out of 10 at rest within last 2
week despite supplemental oxygen for at least 1 hour

R

Baseline
Assessment 1
BIPAP

VapoTherm

2 hours

Assessment 2
Assessment 3

Variable washout period
(up to 1 hour)*

VapoTherm

BIPAP

2 hours

Assessment 4

Preference Survey
* Back to same oxygen level prior to study. Patient may proceed to the next intervention
when they have a dyspnea score ≥ baseline level - 1, or have a dyspnea score of ≥3 by the
end of 1 hour.

Figure 2. Study Overview. In this open-label, randomized, crossover
study, advanced cancer patients with persistent dyspnea were
randomized to either BIPAP followed by VapoTherm, or VapoTherm
followed by BIPAP. The total study duration was up to 5 hours. Four
assessments (before and after each intervention) were conducted during
the study period, with a preference survey at the end.
B. Inclusion Criteria
1. History of advanced cancer, defined as locally advanced, recurrent or
metastatic disease
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2. Patients with persistent dyspnea, defined in this study as dyspnea at
rest with an average intensity level ≥3 out of a Numeric rating scale
from 0 to 10 for at least 2 week and just prior to study initiation, despite
supplemental oxygen of up to 21 L/min to keep oxygen saturation
≥90%
3. Dyspnea is judged clinically to be predominantly due to underlying
malignancy, with or without obstructive lung disease
4. Inpatient at M.D. Anderson Cancer Center
5. Patients with cancer treatment related dyspnea are eligible for this
study if they meet the eligibility criteria above
6. Able to communicate in English
7. Expected life expectancy >1 week
8. Patients with a diagnosis of pneumonia and/or pulmonary embolism
are also eligible for this study if they meet the eligibility criteria above,
with dyspnea ≥2 weeks prior to the diagnosis of pneumonia

C. Exclusion Criteria
1. Patients who remain hypoxic (i.e. O2 saturation <90% despite maximal
oxygen delivery (21 L/min) are not included in this study because they
are considered to have severe life-threatening respiratory failure and
are too unstable for study inclusion.
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2. Hemodynamic instability (heart rate>140 beats/minute, systolic blood
pressure <80mmHg) within 24 hours of study initiation (as per Clinic
Station)
3. Acute respiratory distress requiring intubation
4. Delirium as indicated by a Memorial Delirium Assessment Scale
(MDAS) of 13 or higher
5. Glasglow coma scale <8
6. Excessive airway secretions interfering with BIPAP administration
7. History of facial trauma within 1 month of enrollment
8. Upper GI bleed within 2 weeks or esophageal rupture of enrollment
9. Partial or complete small bowel obstruction or severe nausea/vomiting
(ESAS nausea >7/10) within 48 hours of enrollment
10. Hemoglobin <8 g/dL at the time of enrollment (blood draw within last 2
weeks)
11. Acute exacerbation of COPD or CHF within 2 weeks of enrollment by
history or physical
12. Unwilling to provide informed consent
13. Diagnosis of non-cancer related dyspnea (e.g. COPD, CHF or any
chronic respiratory disease) requiring supplemental home oxygen prior
to hospitalization.

D. Patient Screening and Recruitment
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Newly admitted advanced cancer patients who were potentially dyspneic
were identified through multiple sources, including a daily log of inpatients
initiated on supplemental oxygen or nebulizer treatments the previous day
by respiratory therapy, advanced nurse practitioners from rehabilitation
medicine and thoracic medicine, fellows from the palliative care and other
collaborators.

Initial screening was conducted using Clinic Station. Based on information
from this electronic health record interface, we excluded patients who
were discharged, died, hemodynamically unstable, or had a diagnosis of
curable cancer, COPD exacerbation, CHF exacerbation, small bowel
obstruction, facial trauma or upper GI bleed.

If patients appeared eligible after initial screening, they were approached
for study enrollment by our research staff, usually within 24 hours. A twostage consent process was utilized by first asking patients for their
permission to screen them for study eligibility.

Patients who met all

eligibility criteria were then provided with further information including the
informed consent form, and were invited to participate in this study.

E. Study Interventions
Vapotherm: The Vapotherm 2000i Respiratory Therapy Device was
used (Vapotherm, Stevensville, MD, USA). It was approved by the U.S.
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Food and Drug Administration (FDA) in 2001 (K042245) to “add moisture
to and to warm breathing gases for administration to patients, including
neonates/infant, pediatrics, and adults. The environment of use include
home, hospital or sub-acute institutional settings”.

Patients on the

Vapotherm arm received high flow oxygen via nasal prongs. FiO2 was set
at 100% throughout the intervention period. The level of heat (between
35° and 37°) and oxygen flow (between 10 L/min and 40 L/min) were
adjusted initially by our study respiratory therapist to minimize dyspnea
while keeping the patient comfortable.

BIPAP: The BIPAP Vision Ventilatory Support System was used
(Respironics Inc. Murrysville, Pennsylvania, USA). It was approved by
the FDA in 1998 (K982454) for “spontaneously breathing adult patients
suffering from acute respiratory failure, acute or chronic respiratory
insufficiency, or obstructive sleep apnea in hospitals, or other institutional
settings, under the direction of a physician”. Patients assigned to receive
BIPAP treatment received non-invasive ventilation delivered through a
face or nasal mask. Patients were given a choice of either a ResMed
Latex Free Hospital Nasal Mask R611-735/1 (ResMed Ltd, Bella Vista,
NSW, Australia) or a ResMed Latex Free Hospital Full Face Mask R143340/5 (ResMed Ltd, Bella Vista, NSW, Australia). The mask was adjusted
and connected to a ventilator set in pressure support mode (S/T). To
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minimize discomfort, the system used in this study was leak-tolerant, so
that the mask would not need to be airtight.

After securing the mask, the level of support was started at an inspiratory
pressure of 8 cm of H2O and expiratory pressure of 5 cm of H2O. The
pressures was progressively increased and adjusted to maximize
alleviation of dyspnea and to minimize discomfort, with a target inspiratory
pressure between 8 and 18 cm of H2O, and target expiratory pressure
between 3 and 10 cm of H2O. The FiO2 was kept at 100% throughout the
intervention period.

F. Intervention Duration
One small randomized study of high flow and low flow oxygen via
VapoTherm demonstrated a trend towards improved dyspnea with the
high flow arm after 30 minutes of intervention.

The minimal time for

clinical improvement of dyspnea using BIPAP is not clear from existing
literature.

However, a number of studies have shown improved

oxygenation and physiologic parameters within 1 to 3 hours (Table 1).
Thus, we chose a 2 hour period for each intervention, which should give
patients enough time to derive some treatment benefits.

G. Study Process
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Once the patient signed the informed consent and the patient’s attending
physician was notified, the study interventions were initiated within 24
hours. A standing order regarding BiPAP, Vapotherm and medication use
during the study was placed in the patient’s chart to inform clinical staff of
this study. Clinical nurses caring for the patient were also given further
study information.

A randomization list was prepared by our study

biostatistician for each stratum in advance.

During the study period (up to 5 hours), our research staff conducted
study assessments at 4 time points (Figure 2), and provided close
monitoring. Patients who could not tolerate an intervention because of
discomfort were offered the opportunity to (1) temporarily halt the
intervention and resume when ready, (2) switch to alternative intervention
after a variable washout period (if it has not been tried), or (3) discontinue
the study.

Patients who deteriorated clinically during the study (e.g.

severe respiratory distress, oxygen saturation decreased to <90%,
decreased

mental

status,

hemodynamic

instability)

or

required

breakthrough opioid had to terminate the study prematurely.

At the end of study, patients were offered the opportunity to choose to
remain on BIPAP, Vapotherm or return to standard supplemental oxygen
therapy. We did not provide any followup or monitoring after completion of
study.
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H. Washout Period
While the effect of gas exchange is rapid and not expected to carry over
significantly, the duration of washout period for patients to return to
baseline level of dyspnea after using these interventions has not been
defined. Our group has previously conducted a number of crossover trials
for dyspnea in advanced cancer patients, comparing parenteral vs.
nebulized opioids (30), and air vs. oxygen supplementation (10, 31). The
washout periods were relatively short (0-60 minutes) due to the rapid
nature of gas exchange. No clinical trials have directly compared both
BIPAP and Vapotherm. Among the few crossover trials involving either of
these interventions, the washout period varied from 0-10 minutes for
BIPAP (32, 33) to 60 minutes for Vapotherm (12). Thus, we felt that a
variable wash out period of up to 60 minutes was reasonable for this
feasibility study.

We introduced a variable washout period between the two interventions to
determine the optimal duration required for patients to return to baseline
dyspnea level, which was defined as greater than or equal to the dyspnea
level on Numeric rating scale just prior to starting study minus 1. For
instance, if a patient had dyspnea rating of 5/10 prior to study, then any
score of 4 or above was considered to be back to baseline. During the
washout period, patients were given the same level of supplemental
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oxygen just prior to study initiation. For patients whose dyspnea had not
returned to ≥baseline -1 level at the end of 1 hour, they were able to
proceed to the next intervention only if dyspnea ≥3/10. However, if their
dyspnea level remained <3/10 at the end of 1 hour, they would not be
eligible to proceed to the next intervention.

Patients were asked about their level of dyspnea on a numeric rating scale
every 10 minutes after they have completed the first intervention for up to
1 hour. This allowed us to determine the time for dyspnea to develop, and
whether there is any significant difference between VapoTherm and
BIPAP. To minimize bias in this measurement, patients were only told
that a waiting period of up to 1 hour was required to start the next
intervention, but not the requirement that they need to return to baseline to
proceed.

I. Medication Use
Medications such as opioids, steroids and bronchodilators could have an
effect on dyspnea, and could affect the findings of this study if given
around the study period. While it would be ideal to minimize these cointerventions by ensuring that patients are on stable doses of medications
before starting the study, inpatients have frequent medication changes
during the hospitalization making it difficult to control this factor.
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To minimize the effect of opioids, steroids and bronchodilators on the
measurement of dyspnea during the study, patients who were receiving
scheduled and/or breakthrough doses of these medications for any
indications would need to wait for a short duration prior to initiating study
interventions, defined in this study as at least 1 hour for opioids and
steroids, and 30 minutes for bronchodilators prior to study initiation as prestudy dose.

Patients receiving continuous opioid infusion by patient

controlled analgesia pump were able to enroll onto the study if they have
not required breakthrough doses for at least 1 hour.

During the study period (up to 5 hours), patients who required any
breakthrough opioids (parenteral, oral, inhaled), breakthrough steroids
(parenteral, oral or inhaled) or scheduled/breakthrough bronchodilators
were considered as dropouts, and the study interventions were
discontinued.

Patients could continue to receive scheduled doses of

opioids and steroids during the study period.

J. Study Outcome Measures
This study included 4 main assessments—before and after each of the
two interventions (Figure 2 and Table 2). All study assessment forms can
be found in Appendix A.
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Table 2. Study Outcome Measures
Assessment Items

First
assessment

Demographic variables/Baseline
Medication history
MDAS
ECOG performance status
Physical including weight
Cancer Dyspnoea Scale
Numeric Rating Scale
Modified Borg scale
Adverse events
Vitals
Continuous TCCO2 monitoring
Continuous oximetry monitoring
Respiratory settings
Duration of intervention
Global symptom evaluation
Preference survey
Study satisfaction questions

Second
assessment

Third
assessment

Fourth
assessment

×
×
×
××
××
××
×
×
×

×
×
×
××
××
××
×
×

×
×
×
××
××
××
×
×
×
×
×

×
×
×
×
×
×
×
×
×
××
××
××
×

Abbreviations: ECOG, Eastern Cooperative Oncology Group; MDAS,
Memorial Delirium Assessment Scale; TcCO2 transcutaneous carbon
dioxide
x = one measurement, xx = heart rate, respiratory rate, TcCO2, and O2
saturation were recorded every 30 minutes during each intervention by
using the trend function
1. Baseline Patient Characteristics
Baseline demographics were collected from the patient and/or health
records just prior to initiation of first intervention, and included the
following:
•

Demographics (date of birth, gender, race)

•

Cancer diagnosis (date of diagnosis, cancer type, treatments received)

•

Comorbidities (chronic pulmonary or cardiac conditions such as
COPD, CHF, bronchiectasis)

•

Medications

•

Previous BIPAP/Vapotherm use (number of times, most recent use)
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•

Primary etiology of dyspnea

•

Dyspnea measures (see below for details)

•

To better characterize the dyspnea at baseline, we also used the
Cancer Dyspnoea Scale, a validated 12 item questionnaire specifically
designed to assess the quality of dyspnea in cancer patients (34).
Each item has a score between 1 and 5, with a total score of up to 60,
along with sub-scores for sense of effort, anxiety, and discomfort
(Appendix A).

•

ECOG performance status at the time of study initiation. This is a
validated numeric rating scale with a score from 0 to 4 related to
patient’s functional status (35), where 0=Fully active, able to carry on
all pre-disease performance without restriction; 1=Restricted in
physically strenuous activity but ambulatory and able to carry out work
of a light or sedentary nature, e.g., light house work, office work;
2=Ambulatory and capable of all selfcare but unable to carry out any
work activities. Up and about more than 50% of waking hours;
3=Capable of only limited self care, confined to bed or chair more than
50% of waking hours; 4=Completely disabled. Cannot carry on any
selfcare. Totally confined to bed or chair

•

Memorial Delirium Assessment Scale (MDAS) is a 10 item
questionnaire validated in cancer patients for assessment of delirium
(36). It can be administered by a physician, a nurse or a research
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coordinator, assigning a score between 0 and 30. A score of >13 is
suggestive of delirium
•

Focused physical examination of the cardiorespiratory system, and
included the vitals (heart rate, respiratory rate, blood pressure, oxygen
saturation) as per standard clinical practice

2. Dyspnea Measures
Dyspnea is a subjective sensation experienced by patients. The numeric
rating scale (0=no dyspnea and 10=worst dyspnea) (37-39) and modified
Borg scale (37-40) are two of the most commonly used scales to assess
the severity of dyspnea. As there is no established gold standard for
measurement of dyspnea, we used both scales in this study.

The numeric rating scale is a 0 to 10 categorical scale validated for rating
severity of dyspnea, with 0 denoting no dyspnea, and 10 representing
worst dyspnea (37-39). Patients were asked their level of dyspnea at the
moment of assessment.

The modified Borg scale represents another 0 to 10 categorical scale for
rating the severity of dyspnea. The Borg scale was initially developed to
determine the sensation of exertion with exercise. Overtime, it has been
modified and validated for the assessment of dyspnea.

Although the

range for both numeric rating scale and modified Borg scale is between 0
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and 10, the two scales have different anchors and assess dyspnea
differently. The modified Borg scale has more descriptors throughout its
range, and is designed as a ratio scale in which a rating of 2 represents
half the degree of dyspnea as 4, which is in turn half as severe as 8 (3740).

Both dyspnea assessments were performed immediately prior to initiation
of first intervention (assessment 1), immediately before completion of first
intervention (assessment 2), immediately before the second intervention
(assessment 3) and immediately before completion of second intervention
(assessment 4) (Figure 2).

3. Toxicities
While we did not expect significant side effects from Vapotherm or BIPAP,
it was important to document any common or severe adverse effects.
These included dry eyes, dry mouth, mask discomfort, feeling of
suffocation, stomach bloating, anxiety, trouble eating, trouble drinking,
trouble speaking and trouble sleeping. Since many of these side effects
were not captured in the Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0, we developed a specific patient reported
outcome form for this study in which patients were asked to rate their side
effects from 0 (none) to 10 (worst).
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4. Physiologic Measures
At each of the four assessments, we determined the vital signs (heart rate
(HR), respiratory rate (RR), blood pressure (BP), and oxygen saturation
(O2 sat). O2 saturation was monitored using the Alaris® SpO2 module8200 series oximeter (Alaris Medical Systems, Cardinal Health-Alaris
Products, San Diego, CA, USA). Tissue PCO2 level was monitored using
the Sentec Digital Monitoring System TCO2M® Transcutaneous Monitor,
Novametrix Model #860 (Novametrix Medical Systems Inc., Wallingford,
CT, USA) placed on the skin over the face heated between 37°C and
45°C (41-43). Blood gases were not performed to minimize patient
discomfort.

5. Device Settings
The BIPAP and Vapotherm settings were documented by respiratory
therapy. BIPAP settings included mode, breath type, inspiratory oxygen
(FiO2), respiratory rate, inspiratory pressure (IPAP), expiratory pressure
(EPAP), and average tidal volume (VT).

Vapotherm settings included

FiO2, oxygen flow and temperature.

6. Global Symptom Evaluation and Patient Preference
At the end of each intervention, patients were asked to provide a global
assessment of the device on their breathing (worse, about the same, or
better). If their answer was better, they were asked to rate how much
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better their symptoms were (almost the same, hardly any better at all, a
little better, somewhat better, moderately better, a good deal better, a
great deal better, a very great deal better). If their answer was worse, they
were asked to rate how much worse their symptoms were (almost the
same, hardly worse at all, a little worse, somewhat worse, moderately
worse, a good deal worse, a great deal worse, a very great deal worse).
The global symptom evaluation can help provide an anchor for
determining the minimal clinical important difference for the numeric rating
scale and modified Borg scale. A second independent part of this tool
given out at the end of the study asked patients regarding their satisfaction
with the study. This tool has been used by various symptom researchers
(44, 45).

A preference survey was given to patients at the end of the study who
tried both BIPAP and Vapotherm.

Subjects were asked to directly

compare the two devices regarding dyspnea relief, comfort, overall choice.
Given that no clinical trials have examined both BIPAP and Vapotherm,
this survey was specifically designed for this study.

K. Statistical Analyses
Our primary outcome was to determine estimates of the magnitude of
changes in dyspnea scores before and after each intervention, which
would be compared using a crossover design. We planned to enroll 50
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patients overall, with 25 patients receiving BIPAP first then Vapotherm
second, and with 25 patients receiving Vapotherm first then BIPAP
second). This would allow us to declare as statistically significant a
difference in mean change scores of 0.6 standard deviations between
treatment groups, assuming a two-sided significance level of 0.05 and
80% power. Patients were expected to return to their approximate
baseline score between treatments.

For the purpose of this thesis, the interim data for 16 patients enrolled so
far were analyzed. Descriptive statistics (e.g. means, medians, standard
deviations) were used to describe the preliminary findings regarding
dyspnea scores, adverse effects, vitals and overall preference, and to
minimize repeated comparisons. The paired Student’s t-test was used to
compare continuous variables (e.g. vitals) before and after each
intervention, and the paired Wilcoxon test was used for non-parametric
variables (e.g. numeric rating scale, modified Borg scale and adverse
effects). Upon completion of accrual (i.e. 50 subjects), we would be able to
conduct a more detail statistical analysis to directly compare the findings
between Vapotherm and BIPAP. The Statistical Package for the Social
Sciences (SPSS version 16.0, SPSS Inc., Chicago, Illinois) software was
used for statistical analysis.
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Given the preliminary nature of this analysis, we combined all results
related to BIPAP use from both treatment arms, and also all results related
to Vapotherm use from both treatment arms. In the final analysis, the
results would be analyzed in a crossover fashion if there was no
significant period effect.
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Chapter 3. Study Process
While study design is the most critical part of the research process, the
success of a clinical trial depends on many other factors, including
coordination of study process, commitment and training of research staff,
meticulous data management, satisfactorily addressing the regulatory
aspects of this study, and appropriate resource allocation. This chapter
aims to highlight some of the operational aspects of this clinical trial.

A. Study Protocol and Institutional Approval
The study protocol writing process took approximately 4 months between
October and February 2009, with input from Dr. Bruera, Dr. Hui, Dr. Price
from Critical Care, Dr. Faiz for Pulmonary Medicine, Clarence Finch and
Laura Withers from Respiratory Therapy, and Dr. Palmer from
Biostatistics.

After multiple revisions, it was submitted and eventually

approved by the Clinical Research Committee at M.D. Anderson Cancer
Center on April 8, 2009.

This was subsequently approved by the

institutional review board on July 24, 2009. A copy of the study consent is
provided in the Appendix B. The study was formally activated on August
11, 2009. This clinical trial was registered at ClinicalTrials.gov (registration
number NCT00934128).

B. Standard Operating Procedure
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A 12-page standard operating procedure was created shortly before study
activation. This study manual outlined each of the steps involved in this
study, and defined the specific role for research physician, coordinator and
respiratory therapist (Appendix C). This important document helped to
provide orientation to research staff members, to standardize the study
procedures and to improve communication between team members.

C. Research Team
The research team consisted of a research coordinator, two respiratory
therapists and a research fellow (Dr. Hui).

Dr. Bruera oversaw the

operation of this study, along with the research nurse manager and head
of respiratory therapy.

During the month before and the month after study activation (July to
September 2009), we focused on ensuring all research staff were
comfortable with the study process, optimizing the study forms, and
identifying potentially eligible patients.

Multiple training sessions were

provided to help familiarize each research team member with his/her role
and to improve overall coordination. Training consisted of didactic lectures
with Powerpoint presentations as well as practical mock sessions.

All

members were provided with a copy of the standard operating procedure.
Moreover, Dr. Hui provided one-on-one training for our research
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coordinator on a daily basis for two months to optimize the patient
enrollment process.

The research team met regularly during research meetings (once every 12 weeks) to discuss issues related to the screening and recruitment
process, study assessments, data monitoring and trouble shooting.
Minutes were kept and sent out to team members with action list items to
ensure accountability.

D. Patient Accrual and Trouble Shooting
One of the major challenges of this study related to patient accrual.
Before study activation, Dr. Hui presented at the Critical Care
departmental

meeting,

palliative

care

departmental

meeting,

and

respiratory therapy team meetings to promote this study.

We initially relied predominantly on clinical respiratory therapists to
provide us with names of patients who may be dyspneic. However, we
soon realized that this referral process had limited success, likely due to
the fact that clinical respiratory therapists are generally unfamiliar with
clinical trials. The palliative care team referred patients regularly, although
those patients were generally too ill for enrollment. In October 2009, we
started receiving an automated list of patients who were newly started on
oxygen therapy or nebulizer treatments throughout the hospital. We also
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engaged the advanced nurse practitioners from Thoracic Medicine and
Rehabilitation Team, who started to make regular referrals.

To improve accountability and participation, we sent out e-mails once to
twice a week to referring sources to update them regarding any progress
in recruitment, and to encourage further referrals.

Since October 2009,

this study has been able to consistently enroll patients.

E. Data Management
We created a tracking Excel database to facilitate daily screening of
potentially eligible patients. This tracking database consisted of patient
medical record numbers, date of referral, source of referral, patient
location, reasons for ineligibility or refusals (if applicable). It provided an
up-to-date summary of patient recruitment.

An Access database was created by our departmental data analyst to
record information captured in this study.

Data were entered in this

database within 1 week of patient enrollment, and periodically checked for
accuracy and completeness.

F. Study Funding and Budget
Clinical research can be expensive. The hiring of research staff, use of
equipment and study supplies can be costly, depending on nature of the
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study. A budget was created for this clinical trial (Appendix). This budget
included only the cost of equipment and supplies. The cost of hiring
research personnel was not included as it was covered by our
departmental funds.
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Chapter 4. Preliminary Results
A. Patient Accrual and Enrollment
Over 800 patients were screened during the past 8 months. As shown in
Figure

3,

a

large

proportion

of

the

referrals

were

from

the

oxygen/nebulizer log, which was generated automatically every day.
Referrals from thoracic medicine were most likely to be enrolled.

700
Number of referrals

600
500
400
300
200
100
0
Not enrolled
Enrolled

Oxygen log

Palliative
Care

Respiratory
therapy

Thoracic
medicine

Rehab
medicine

Others
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90

43

27

21

21

7

5

0

3

1

0

Figure 3. Referral Sources

The study flow chart is shown in Figure 4.

Approximately 30% were

discharged or died before we completed screening, reflecting the rapid
pace of hospital discharge.

Among the 549 patients who completed

screening, almost 90% were ineligible, with a diagnosis of curable cancer,
not dyspneic enough, contraindications to BIPAP, delirium and non-cancer
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dyspnea being the major reasons.

Among the 62 eligible patients who

completed screening, 16 (26%) enrolled onto the study.

Only 5 of 16 patients were able to complete both BIPAP and Vapotherm.
As shown in Figure 3, 4 patients did not proceed to the second
intervention after the full 1 hour washout period because they experienced
prolonged relief of dyspnea and never returned to baseline (3 after BIPAP
and 1 after Vapotherm).

Two patients who completed BIPAP as the first

intervention dropout out during the washout period because of fatigue and
pain requiring opioid use. Three patients who tried BIPAP as the second
intervention had to discontinue prematurely because they were unable to
tolerate BIPAP (claustrophobia, positive pressure, and nausea after 45
minutes of BIPAP).

Two other patients had difficulty tolerating both

devices due to high levels of anxiety.

36

Figure 4. CONSORT Diagram
B. Baseline Characteristics
The baseline characteristics for the 16 patients enrolled onto this study so
far are shown in Table 3. Almost half of them had lung cancer, and a
majority had metastatic disease.

Reasons for dyspnea included

involvement of the lung parenchyma, pleural effusion, cachexia and
lymphagitic carcinomatosis. Pneumonia and pulmonary embolism were
also present in a small proportion of patients. Importantly, a substantial
number of these patients were already on supplemental oxygen,
bronchodilators, opioids and steroids.
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Table 3. Patient Characteristics
Clinical characteristics
Age, median (range)
Female sex
Race
Caucasian
African American
Cancer type
Lung
Breast
Gastrointestinal
Others
Cancer stage
Metastatic
Locally advanced
Co-morbidities
COPD
Asthma
CHF
Bronchiectasis
Performance Status
3
4
Reasons for dyspnea**
Lung parenchymal involvement
Pleural effusion
Cachexia/muscle weakness
Lymphangitic carcinomatosis
Pneumonia
Pulmonary embolism
Baseline medications
Supplemental oxygen
Bronchodilators
Opioids
Steroids
Previous experience with BIPAP/Vapotherm
BIPAP
Vapotherm

N (%)*
62.5 (29-79)
9 (56%)
14 (87%)
2 (13%)
7 (44%)
4 (25%)
2 (13%)
3 (18%)
12 (75%)
4 (25%)
4 (25%)
0
0
0
13 (81%)
3 (19%)
12 (75%)
6 (38%)
6 (38%)
2 (13%)
3 (19%)
1 (6%)
16 (100%)
16 (100%)
15 (94%)
8 (50%)
1 (6%)
0

C. Dyspnea Scores
At baseline, the median dyspnea numeric rating scale was 7/10
(interquartile range 5-8), and the median modified Borg scale was 4/10 (37). Using the Cancer Dyspnea Scale, our cohort reported a sense of effort
subscale score of 11/20 (standard deviation (SD) 5), anxiety subscale
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score of 7/16 (SD 5), discomfort subscale score of 6/12 (SD 3), and a total
dyspnea score of 23/48 (SD 8).

The changes in dyspnea score by numeric rating scale and modified Borg
scale are shown in Figure 5.

Overall, BIPAP was associated with a

median change in numeric rating score of -3 (N=10, interquartile range
-6.3 to -1, p=0.007) and modified Borg score of -1 (N=10, interquartile
range -3 to 0.3, p=0.058), while Vapotherm was associated with a median
change in numeric rating score of -2 (N=9, interquartile range -3 to -1,
p=0.011) and modified Borg score of -2.5 (N=8, interquartile range -5.5 to
-0.1, p=0.051).

Global assessment of dyspnea was consistent with the overall reduction of
dyspnea scores, and confirmed that patient found the interventions helpful
for their shortness of breath. As shown in Figure 6, 10 of 11 patients who
successfully completed BIPAP reported that it improved their dyspnea,
with 4 of them experiencing at least a good deal of relief. Seven of 9
patients found Vapotherm to be useful in improving their dyspnea.
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Figure 5. Changes in Dyspnea Scores. The numeric rating scale was
plotted for each patient before and after (A) BIPAP and (B) Vapotherm.
The Borg scale was also plotted for each patient before and after (C)
BIPAP and (D) Vapotherm.
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Figure 6. Global Assessment of Dyspnea after BIPAP and Vapotherm
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D. Physiologic Measures
The physiologic changes before and after study interventions are shown in
Table 4.

After BIPAP, patients generally had a lower heart rate,

respiratory rate and oxygen saturation.

However, the transcutaneous

carbon dioxide level did not change significantly.

Vapotherm was

associated with improved oxygenation and decreased respiratory rate.
Table 4. Physiologic Measures
Average values
Heart rate (beats per
minute)
Respiratory rate (per
minute)
Systolic blood
pressure (mmHg)
Diastolic blood
pressure (mmHg)
Oxygen saturation
(%)
Transcutaneous
carbon dioxide level

Before
(SD)

97
(15)
26
(5)
128
(20)
74
(10)
94
(6)
35
(7)

BIPAP
After
Change
(SD)
(SD)

96
(8)
22
(5)
128
(14)
75
(17)
100
(1)
38
(9)

-6
(5)
-4
(2)
-9
(12)
0
(10)
+8
(5)
+2
(3)

P-value

Before
(SD)

0.01

107
(17)
26
(10)
143
(12)
84
(5)
92
(4)
36
(4)

0.002
0.11
0.94
0.006
0.13

Vapotherm
After
Change
(SD)
(SD)

105
(14)
22
(9)
142
(22)
85
(9)
97
(1)
33
(5)

-3
(7)
-4
(10)
-2
(22)
+1
(9)
+5
(3)
-2
(2)

P-value

0.45
0.32
0.86
0.77
0.01
0.04

Abbreviation: SD, standard deviation
E. Adverse Effects
As shown in Table 5, patients on BIPAP reported some difficulties drinking
and talking as well as the mask being uncomfortable, which was balanced
by less discomfort with nasal prong use. Remarkably, patients reported a
lesser sensation of suffocation on BIPAP. The main adverse effect for
Vapotherm was moisture in the nose.
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No significant life-threatening adverse events were documented. Four of
16 patients died within 1 month of study completion. The deaths were not
attributed to this study, but reflected the poor prognosis of our patient
population.
Table 5. Patient Reported Adverse Effects Before and After
BIPAP/Vapotherm
Median
Dry eyes
Eye irritation
Moist nose
Nasal prongs
uncomfortable
Mask painful
Suffocating
Bloating
Feel anxious
Trouble eating
Trouble drinking
Trouble talking
Trouble
sleeping

Before
(IQR)
2
(0-3.8)
0
(0-1.8)
2
(0.5, 2.8)
4.5
(0.5, 5.8)
0
(0, 0)
3
(0, 4.8)
0.5
(0, 2.8)
1.5
(0, 2.0)
4
(0.5, 6)
2
(0, 3)
1.5
(0, 4.3)
2.5
(0.3, 5.8)

BIPAP
After
Change
(IQR)
(IQR)
1.5
0
(0, 4.5)
(0, 0)
0
0
(0, 3)
(-0.75, 0)
0
0
(0, 2)
(-1.75, 0)
0
-2.5
(0, 0)
(-3.8,-1.2)
0.5
+1.5
(0, 3)
(0.8, 2.3)
0
-2.5
(0, 0.8)
(-3.8, 0)
0
0
(0, 1.8)
(-1, 0)
0
0
(0, 2.8)
(-0.8, 0)
3.5
-2
(0.5, 6.5) (-2.8, 2)
3.5
0.5
(0, 7)
(-1.8, 4.5)
6.5
+2
(2.8, 7.8)
(0, 7)
3.5
0
(1.3, 5)
(-1, 2.3)

P-value
1.0
0.58
0.75
0.007
0.07
0.03
0.59
0.71
0.76
0.44
0.07
0.67

Before
(IQR)
1
(0, 3)
0
(0, 5)
2
(0, 5)
0
(0, 3)
0
(0, 7)
3
(1, 6)
5
(0, 6)
3
(0, 6)
0
(0, 4)
5
(0, 6)
7
(5, 8)

Vapotherm
After (IQR) Change
(IQR)
0
-1
(0, 3)
(-3, 0)
0
0
(0, 0)
(-3.5, 0)
4.5
+1.5
(2.5, 6.3) (-0.3, 3.3)
2
0
(0, 2.5)
(-0.3,1.8)
0.5
(0, 1.8)
1
(0, 2.3)
0
(0, 1)
1
(0, 5.5)
0
(0, 0.5)
1
(0, 2.8)
0
(0, 1.3)

0
(-0.3,0.3)
-1
(-1.8, 0)
-2
(-4.3, 0)
0
(-0.3, 0.3)
0
(0, 0)
0
(-1.8, 0.5)
-4.5
(-7.3,-1.5)

P-value
0.07
0.10
0.13
0.50
0.71
0.04
0.07
1.0
0.66
0.50
0.03

Abbreviations: IQR, interquartile range; “-“, not applicable
F. Washout Period
The duration of washout period was an important outcome, as it is a
measure of the duration of therapeutic effect after discontinuation of the
first intervention. Three of 6 patients who completed BIPAP and 1 of 7
who completed Vapotherm as the first intervention experienced significant
relief of dyspnea (i.e. ≤2/10) even after they returned to supplemental
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oxygen for 1 hour, and were not eligible to proceed to the next phase of
the study.
Table 6. Washout Period Dyspnea Scores and Outcome
Patient
#
4
5
6
9
14
15
1
3
8
10
11
13
16

First
treatment
BIPAP
BIPAP
BIPAP
BIPAP
BIPAP
BIPAP
Vapotherm
Vapotherm
Vapotherm
Vapotherm
Vapotherm
Vapotherm
Vapotherm

Baseline
dyspnea
7
8
5
7
7
5
8
6
5
8
10
3
9

Washout Period Numeric Rating Scores
0
10
20
30
40
50
60
min min min min min min min
6
2
1
2
2
2
3
2
3
1
1
2
2
2
2
5
6
3
4
3
4
0
0
0
0
1
1
2
2
2
2
2
2
2
8
7
3
3
5
3
3
4
5
7
4
2
1
1
4
2
2
2
3
6
7
7
6
7
6
6

nd

Tried 2
treatment
Yes
No
Yes
No*
No
No
Yes
Yes
Yes
Yes
No
Yes
Yes

*This patient dropped out of study early during the washout period due to
fatigue.
G. Patient Preference and Satisfaction
In addition to dyspnea scores and global assessments, patients who tried
both interventions were asked at the end of the study to directly compare
Vapotherm and BIPAP, and provide us with their overall preference.

Among the 5 individuals who completed the entire study, 2 patients
preferred Vapotherm for relief of dyspnea, 2 patients preferred BIPAP, and
one liked both. However, 4 of 5 patients reported BIPAP as causing more
discomfort than Vapotherm.

Taking all factors into consideration, 2

patients preferred Vapotherm, 2 patients preferred BIPAP, and 1 preferred
both.
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A satisfaction survey was completed by 10 patients who completed a
substantial part of this study.

All 10 patients agreed that this was

“worthwhile” and that they would “do this study again” and “recommend
this study to others”.

Seven of 10 patients agreed that this study

“improved his/her quality of life”.
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Chapter 5. Discussion
We presented the preliminary results of an open label randomized Phase
II clinical trial comparing BIPAP and Vapotherm for the relief of persistent
dyspnea among inpatients with advanced cancer. After screening over
800 patients, we found 62 (8%) eligible individuals, and enrolled 16 out of
a planned total of 50 patients. Despite challenges with recruitment and
attrition, our results supported that both devices provide significant relief
for dyspnea and decrease the work of breathing.

Further efforts to

complete this study are warranted.

A. Recruitment and Retention
This study had several unique challenges, making it difficult to recruit
patients. First, our study population involved advanced cancer patients
with persistent dyspnea, who represent a population with extremely poor
prognosis and low performance status. In fact, many of these patients
were delirious, in acute distress, or too weak/tired to participate in our
study. Second, our study focused on recruiting patients with persistent
rather than episodic dyspnea because we believed that BIPAP and
Vapotherm are best suited for this purpose. This significantly limits the
number of eligible subjects as persistent dyspnea is not as common (46).
Third, only hospitalized patients were included in this study.

These

patients were generally admitted for acute illness or complications, with
rapid changes in their health status. This, coupled with the busy hospital

45

course

with

multiple

investigations

and/or

procedures,

and

the

unpredictable discharge planning, made it difficult to find a window of
opportunity for patients to participate in the study. Finally, patients were
generally less inclined to enroll onto supportive care studies than cancer
treatment trials (47). Thus, successful recruitment required screening of
large number of patients, regular monitoring, impeccable coordination,
cohesive teamwork and a flexible schedule. It was encouraging that we
were able to enroll 16 patients between October 2009 and March 2010,
representing approximately one third of the accrual target. Putting this in
perspective, a review of the 6 randomized clinical trials included in a
recent metaanalysis examining the effect of oxygen for dyspnea showed
the median sample size to be 24 (range 7-51) (3).

Despite the relatively short duration of this study, attrition represented
another major challenge. Only 5 of 16 subjects were able to complete the
entire study. Four subjects did not proceed to the second phase because
their dyspnea score were too low after the first intervention. Five subjects
had some difficulty tolerating BIPAP due to anxiety, claustrophobia,
positive airway pressure and nausea.

Our finding is consistent with

literature which showed that 10-30% of patients have BIPAP intolerance
(48, 49).

Interestingly, 2 of these patients had difficulty tolerating

Vapotherm as well. Thus, BIPAP and Vapotherm may not be appropriate
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for all patients, particularly those who are frail and in distress.

Better

patient selection and longer washout period are necessary for future trials.

B. Improvement in Dyspnea
The numeric rating scale and modified Borg scale indicated some
improvement with both BIPAP and Vapotherm. Due to the small sample
size, we did not compare the change in dyspnea scores between the two
interventions.

However, the numeric rating scale appeared to favor

BIPAP, while the modified Borg scale showed greater improvement with
Vapotherm.

This discrepancy may be due to random variation, the

different sensitivity of the scales, and/or how patients interpreted these
tools. A larger sample size with formal statistical testing is necessary.

A difference of 21 mm on a 100 mm visual analog scale was found to be
clinically significant in a study of heart failure patients (50).

However,

there is no established minimal clinical important difference for both
numeric rating scale and modified Borg scale (37). Thus, we included a
global symptom assessment at the end of each intervention. Consistent
with the dyspnea scores, a majority of the patients reported the devices to
be useful in relieving their dyspnea. This benefit, if confirmed, is highly
encouraging given that a majority of our patients were already on maximal
supportive measures with supplemental oxygen, steroids, opioids and
bronchodilators. As hypothesized, BIPAP and Vapotherm may exert their

47

therapeutic effects on dyspnea through multiple mechanisms rather than
just improved oxygenation alone.

We were somewhat surprised by the prolonged washout period, as other
studies demonstrated that patients become dyspneic shortly after
discontinuation of supplemental oxygen (10, 31). Three patients who tried
BIPAP and one on Vapotherm reported significant and long lasting
improvement after discontinuation of the respective interventions.

We

initially hypothesized that BIPAP is better than Vapotherm for relief of
dyspnea, given that it not only improves oxygenation, but also ventilation,
muscle fatigue and alveolar recruitment. Upon completion of accrual, we
would be testing this specific hypothesis.

C. Toxicities
Safety is an important outcome for this study. Patients who were able to
tolerate the devices reported minimal toxicities. While the BIPAP mask
was associated with some discomfort, patients also found the nasal
prongs to be somewhat uncomfortable. Although BIPAP may result in the
sensation of suffocation in some patients, our patients reported a
reduction in this symptom while on BIPAP, consistent with its beneficial
effort on dyspnea.

D. Improvement in Physiologic Measures
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Our preliminary examination of physiologic measures demonstrated that
the oxygen saturation improved while the respiratory rate decreased by
approximately 4/minute with both interventions, consistent with a
decreased work of breathing. Interestingly, tissue carbon dioxide level did
not drop significantly with BIPAP. However, it is important to point out that
a majority of the patients enrolled so far had hypoxemic respiratory failure
rather than hypercapneic respiratory failure.
transcutaneous

carbon

dioxide

level,

these

As shown by the
patients

were

in

a

hyperventilation state at baseline, and thus BIPAP had limited impact on
this parameter.

E. Limitations
This study has several limitations. First, the primary outcome measure of
dyspnea was a subjective numeric rating scale.

Rather than a direct

benefit from the study interventions, the positive finding could simply be
the result of placebo and/or trial effect, such as positive interaction with
study staff. To assess dyspnea from different angles, we incorporated two
different dyspnea scales, global assessment, washout period assessment
and a number of objective secondary endpoints such as vital signs.
Second, ascertainment bias was particularly important as blinding was not
possible for this study. Third, we only examined the study interventions
for 2 hours each and in hospitalized patients only. The longer term benefit
in outpatients is unclear. Further studies are necessary to examine these
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options. Finally, it is important to recognize the interim results reported
here were based on 16 patients only, and our conclusions could change
with a larger sample size.

F. Conclusions
Based on the preliminary analysis of 16 patients, we found that BIPAP and
Vapotherm provided excellent dyspnea relief for advanced cancer patients
who had persistent dyspnea despite standard therapeutic options. The
use of these devices was associated with minimal toxicities and positive
physiologic changes. We were also able to demonstrate the feasibility of
enrolling very sick patients onto this study. Our next step would be to
complete this clinical trial, which would allow us to directly compare the
efficacy of these two modalities. If the findings remained positive, larger,
more definitive research studies examining these interventions for longer
periods are warranted.
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Appendix
A. Study Forms
Patient Demographics and Baseline Characteristics for Dyspnea Study
Assessment #1 Only

Age:______________

Gender:___________

Ethnicity:

White

Asian

Black
Cancer Diagnosis:
Date of diagnosis:
Cancer histology:
Cancer stage:
Cancer treatments received
(include
systemic therapy and
radiation):

Medical Co-morbidities:
COPD
Asthma
CHF
Bronchiectasis
Others




Date of
Birth:___________

Hispanic
Other____________

____________________________
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________


Yes

No

Yes

No

Yes

No

Yes

No
____________________________
____________________________
____________________________

Reason for dyspnea:

____________________________

Current Medications:
Bronchodilators (e.g.
Salbutamol):

Please list name, dosage, frequency and
route
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________

Steroids (e.g. prednisone):
Opioids (e.g. morphine):
Others

Research Staff Signature:
________________
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Previous BIPAP/CPAP/Vapotherm

BIPAP

If yes, How many times in the past? _____
When was the last time? _____
What was reason? _____



CPAP

If yes, How many times in the past? _____
When was the last time? _____
What was reason? _____



Vapotherm

If yes, How many times in the past? _____
When was the last time? _____
What was reason? _____

Current ECOG Performance Status:

1

2
Physical Examination Findings:
Weight (kg)
Heart rate (beats/minute)
Respiratory rate (/minute)
Blood pressure
(systolic/diastolic)
Temperature (°F)
Oxygen saturation (%)
Supplemental oxygen (L/min)
Respiratory examination
Cardiac examination

3
4




____________________________
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________
____________________________

Research Staff Signature:
________________

52

Numeric Rating Scale for Screening Purposes (2 Step Consent)
Please circle the number to indicate the average level of your shortness of breath over
the last 2 weeks.
No shortness
of breath
0

1

2

3

4

5

6

7

8

9

Worst
possible
shortness
of breath
10

Please circle the number to indicate the level of your shortness of breath NOW.
No shortness
of breath
0

1

2

3

4

5

6

7

8

9

Worst
possible
shortness
of breath
10

Research Staff Only
 Yes

Patient agreed to be screened:
If patient disagreed, please
indicate reason(s):

 No

___________________________
___________________________
___________________________
 Yes

After screening, patient is eligible:
If not eligible, please
indicate reason(s):

 No

___________________________
___________________________
___________________________

Research Staff Signature:
________________
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Numeric Rating Scale for Study Assessments
Assessment #1, #2, #3, #4 (please circle)
Please circle the number to indicate the level of your shortness of breath NOW.
No shortness
of breath
0

1

2

3

4

5

6

7

8

Research Staff Signature:
________________
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9

Worst
possible
shortness
of breath
10

Modified Borg Scale for Study Assessments
Assessment #1, #2, #3, #4 (please circle)
Please circle the number that best describes the sensation of your shortness of
breath NOW (e.g. extremely weak sensation, extremely strong sensation).
0

Nothing at all

0.5

Extremely weak (just noticeable)

1

Very weak

2

Weak (light)

3

Moderate

4

Somewhat strong

5

Strong (heavy)

6
7

Very strong

8
9
10

Extremely strong (almost maximal)

*

Maximal

Research Staff Signature:
________________
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Cancer Dyspnoea Scale
Assessment #1 only

Research Staff Signature:
________________

56

Global Symptom Evaluation
Assessments #2 only

Research Staff Signature:
________________
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Global Symptom Evaluation and Study Satisfaction
Assessment #4 only

Research Staff Signature:
________________
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Patient Preference Survey
Assessment #4 only
5. Which of the following causes you the
most discomfort? (Choose one)
BIPAP
VapoTherm
Both
None of above

1. How would you consider your breathing
while on BIPAP as compared to before the
study? (Choose one)
Much worse
Worse
Same
Better
Much better

6. Which of the following would you prefer
the most overall, taking all factors into
consideration? (Choose one)
BIPAP
VapoTherm
Both
None of above

2. How would you consider your breathing
while on VapoTherm as compared to before
the study? (Choose one)
Much worse
Worse
Same
Better
Much better

7. If you have tried both nasal and facial
mask while on BIPAP, which one do you
prefer more? (Choose one)
Facial mask
Nasal mask
Both
None of above

3. How would you consider your breathing
comparing BIPAP to VapoTherm? (Choose
one)
BIPAP is much better
BIPAP is better
Same
VapoTherm is better
VapoTherm is much better
4. Which of the following would you prefer
the most for relief of your shortness of
breath? (Choose one)
BIPAP
VapoTherm
Both
None of above
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Research Staff Signature: ________________
Washout Period Data Collection and Decision Making Sheet
During washout period only
Baseline dyspnea score (assessment #1)

_____/10

nd

Cutoff score for starting 2 intervention (if baseline dyspnea score = 3, then the
cutoff score = 3; otherwise, subtract 1 from the baseline dyspnea score to get
cutoff score)

_____/10

Please indicate patients’ level of dyspnea during the washout period:
Time
Interval
Dyspnea score
Instruction
(24:00)
nd
10 minute
_____/10
Proceed to 2 intervention if ≥cutoff; otherwise,
wait 10 minutes and repeat assessment
nd

20 minute

_____/10

Proceed to 2 intervention if ≥cutoff; otherwise,
wait 10 minutes and repeat assessment

30 minute

_____/10

Proceed to 2 intervention if ≥cutoff; otherwise,
wait 10 minutes and repeat assessment

40 minute

_____/10

Proceed to 2 intervention if ≥cutoff; otherwise,
wait 10 minutes and repeat assessment

50 minute

_____/10

Proceed to 2 intervention if ≥cutoff; otherwise,
wait 10 minutes and repeat assessment

60 minute

_____/10

Proceed to 2 intervention if ≥cutoff OR if score
≥3/10; otherwise, terminate study

nd

nd

nd

nd
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Research Staff Signature: ________________
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Patient Reported Adverse Effect Form
Assessment #1, #2, #3, #4 (please circle)
Please indicate if you experience any of the following now:
Worst
possible

Not at all
I have dry eyes

0

1

2

3

4

5

6

7

8

9

10

I have eye irritation

0

1

2

3

4

5

6

7

8

9

10

Moisture in my nose

0

1

2

3

4

5

6

7

8

9

10

The nasal prong is
uncomfortable

0

1

2

3

4

5

6

7

8

9

10

The mask is painful

0

1

2

3

4

5

6

7

8

9

10

I feel I am suffocating

0

1

2

3

4

5

6

7

8

9

10

My stomach is bloated

0

1

2

3

4

5

6

7

8

9

10

I feel anxious

0

1

2

3

4

5

6

7

8

9

10

I have trouble eating

0

1

2

3

4

5

6

7

8

9

10

I have trouble drinking

0

1

2

3

4

5

6

7

8

9

10

I have trouble talking

0

1

2

3

4

5

6

7

8

9

10

I have trouble sleeping

0

1

2

3

4

5

6

7

8

9

10

Others
0
Please specify:_____________

1

2

3

4

5

6

7

8

9

10

Others
0
Please specify:_____________

1

2

3

4

5

6

7

8

9

10

Research Staff Signature: ________________
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Dropout
Assessment #2, #3, #4 (please circle)
Dropout (only if patient unable to complete study)
Time of study dropout
_____________________
Phase of study dropout







Reason(s) for dropout

_____________________
_____________________
_____________________
_____________________
_____________________

Before starting intervention 1
During intervention 1
During washout period
During intervention 2
After intervention 2

Research Staff Signature: ________________
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Data Collection for Respiratory Settings
Assessment
#1

Assessment #2
30/60/90/120min

Assessment
#3

Assessment #4
30/60/90/120min

Start time
End time
Device (Bipap,
Vapotherm or
Suppl. 02)
Interface (facial
mask, nasal mask,
nasal prongs)
Fi02 (%)
Reading
IPAP (mmHg)
Reading
EPAP (mmHg)
Reading
O2 flow (Vapotherm
or Supplemental
O2) Reading
TcC02 (mmHg)
Q30min
Sp02 (%)
Q30min
RR (minute)
HR (minute)
BP (systolic/
diastolic)
Temp (ºF)
Comments

Research Staff Signature: __________________________
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B. Study Consent

INFORMED CONSENT/AUTHORIZATION FOR
PARTICIPATION IN RESEARCH
An Exploratory Trial of Bilevel Positive Airway Pressure Device
and High Flow Oxygen for Persistent Dyspnea in Advanced
Cancer Patients
2009-0164
Study Chair: Eduardo Bruera
1
.
Participant’s Name

Medical Record Number

You are being asked to take part in this clinical research study at The
University of Texas M. D. Anderson Cancer Center ("M. D. Anderson").
This consent form explains why this research study is being done and
what your role will be if you choose to take part. This form also
describes the possible risks connected with being in this study. After
reviewing this information with the person responsible for your
enrollment, you should know enough to be able to make an informed
decision on whether you want to take part in the study.
You are being asked to take part in this study because you have
advanced cancer and are experiencing shortness of breath.
DESCRIPTION OF RESEARCH
2. PURPOSE OF STUDY
The goal of this clinical research study is to learn if specialized
breathing devices reduce the sensation of shortness of breath in
patients with advanced cancer who are experiencing shortness of
breath. Researchers want to learn if these devices can help to
control shortness of breath.
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The 2 devices being tested and compared are called BiPAP (bilevel
positive airway pressure) and Vapotherm.
3. DESCRIPTION OF STUDY
Study Devices
The BiPAP device is designed to help people get more air in and out
of their lungs without using as much effort as regular breathing. The
air is given through a mask, and the amount of air can be set to
different levels.
The Vapotherm device is also designed to deliver air in and out of the
lungs. The air is warmed, filtered for bacteria, and then delivered
through the nose using a tube under the nostrils.
Screening Tests
Signing this consent form does not mean that you will be able to take
part in this study. You will have "screening tests” to help the doctor
decide if you are eligible to take part in this study. The following tests
and procedures will be performed:
You will have a physical exam, including measurement of your
weight and vital signs (heart rate, breathing rate, blood
pressure, and temperature).
The level of oxygen in your blood will be measured using a soft
clamp placed on your finger.
You will be asked about your breathing, and you will rate how
hard it is to breathe.
You will complete 3 questionnaires. Two (2) of them have
questions about the breathing symptoms, and the third
questionnaire has questions about any confusion you may be
experiencing. This should take a total of less than 15 minutes.
From your medical record, the study staff will collect information
about your age, sex, race, cancer type, any drugs you are
taking, and possible causes of shortness of breath.
The research staff will discuss the screening test results with you. If
the screening tests show that you are not eligible to take part in the
study, you will not be enrolled. Other treatment options will be
discussed with you.
Study Groups
If you are found to be eligible to take part in this study, you will be
randomly assigned (as in the flip of a coin) to 1 of 2 groups.
Group 1 will receive air through BiPAP for up to 2 hours and
then air through Vapotherm for up to 2 hours.
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Group 2 will receive air through Vapotherm for up to 2 hours
and then air through BiPAP for up to 2 hours.
The study staff will help you use the devices.
If you have trouble with one of the devices, you can be switched to the
other device before the 2-hour period is over.
After using the first device, you will wait for up to 60 minutes before
switching over to the other device. This waiting period will occur no
matter if you used the first device for the full 2 hours or not.
During the waiting period, you will return to the same air delivery
device and oxygen level that you were using just before you started the
study. The study staff will also be checking to see if you are still
eligible to use the second device.
Study Tests
During the study period, your vital signs and level of air breathed out
will be recorded using a measuring device on your chest.
Before and after using the devices, you will rate how hard it is to catch
your breath.
After using the second device, you will fill out a questionnaire that has
questions about which device you prefer. This should take less than 5
minutes.
Length of Study
You will be on this study for up to 5 hours. You will be taken off study
and the device will be stopped if intolerable side effects occur while
using a study device.
Use of Other Drugs
During the 4-5 hour study period, you will not be allowed to take certain
drugs for standard care that may affect the study tests. These drugs
include certain pain-killer drugs (such as morphine and
hydromorphone), steroids (such as prednisone and dexamethasone),
and inhaled drugs (such as ipratropium and salbutamol).
Any doses of inhaled drugs (regularly scheduled doses and "as
needed" doses) and any "as needed" doses of pain-killer drugs and
steroids that fall within the 4-5 hour study period will be put on hold and
will be given to you right after the study is complete.
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You may, however, choose to take these drugs, either because your
shortness of breath is not controlled, or because these drugs are
needed to treat other problems (such as pain). If you and your doctor
decide that you should take these drugs during the study period, you
will be taken off study so you can receive these drugs. The reason for
stopping your study participation is that these drugs may affect how
you rate your shortness of breath.
This is an investigational study. The BIPAP and Vapotherm devices
are commercially available and FDA approved for delivering oxygen
when medically needed, including in patients with advanced cancer.
The investigational part of this study is to collect information from
asking patients to rate how well the study devices may affect shortness
of breath.
There will be no cost to you for using the breathing devices during the
study.
Up to 50 patients will be enrolled in this study. All will be enrolled at M.
D. Anderson.
4. RISKS, SIDE EFFECTS, AND DISCOMFORTS TO PARTICIPANTS
While on this study, you are at risk for side effects. You should discuss
these with the study doctor. The known side effects are listed in this
form, but they will vary from person to person. In most cases, the side
effects will go away shortly after the device is stopped but in some
cases the side effects may last longer.
"Likely" side effects occur in more than 20% of patients, "common"
side effects occur in 3-20% of patients, and "rare" side effects occur in
fewer than 3% of patients.
BiPAP Side Effects
The BiPAP face mask may likely cause discomfort.
BiPAP may commonly cause stomach bloating and/or drying of the
eyes.
BiPAP may rarely cause pink eye.
Vapotherm Side Effects
Vapotherm may likely cause uncomfortable moisture in the nose.
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Vapotherm may rarely cause the feeling of breathing difficulty (like you
are choking or suffocating but are actually not).
Other Risks
Questionnaires may contain questions that are sensitive in nature.
You may refuse to answer any question that makes you feel
uncomfortable. If you have concerns after completing the
questionnaire, you are encouraged to contact your doctor or the study
chair.
This study may involve unpredictable risks to the participants.

5. POTENTIAL BENEFITS
The breathing devices may help to control the shortness of breath
during the 4-5 hour study period. Future patients may benefit from
what is learned in this study. There may be no benefits for you in
this study.
6. ALTERNATE PROCEDURES OR TREATMENTS
You may choose not to take part in this study. You may choose to
receive drugs for shortness of breath. The drugs may include, for
example, opioids (pain-relievers) or bronchodilators (airway-wideners).
You may use either BiPAP or Vapotherm without taking part in this
study.
You may choose to receive other investigational therapy, if available.
You may choose not to have treatment for shortness of breath at all.
In all cases, you will receive appropriate medical care.
I understand that the following statements about this study are
true:
7.

M. D. Anderson may benefit financially from my participation and/or
from what is learned in this study.

8.

I may ask the study chair any questions I have about this study,
including questions about the costs. I may contact the study chair, Dr.
Eduardo Bruera, at 713-792-6085. I may also contact the Chair of M.
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D. Anderson's IRB at 713-792-2933 with any questions that have to
do with this study or my rights as a study participant.
9.

My participation in this research study is strictly voluntary. I may
refuse to take part in this study without any penalty or loss of benefits
to which I am otherwise entitled. I may also withdraw from
participation in this study at any time without any penalty or loss of
benefits. I should first discuss leaving the study with my doctor. If I
withdraw from this study, I may still be treated at M. D. Anderson.

10. I understand that the study may be changed or stopped at any time by
the study chair, the U.S. Food and Drug Administration (FDA), the
Office for Human Research Protections (OHRP) (a regulatory agency
that oversees research in humans), or the IRB of M. D. Anderson.
11. I will be informed of any new findings that might affect my willingness
to continue taking part in the study.
12. M. D. Anderson will take appropriate steps to keep my personal health
information private. However, there is no guarantee of absolute
privacy. Federal agencies (such as the FDA and the OHRP), and the
IRB of M. D. Anderson might review my record to collect data or to
check that the research is being done safely and correctly. In some
situations, the FDA could be required to reveal the names of
participants.
13. If I suffer injury as a direct result of taking part in this study, M. D.
Anderson will provide medical care. However, this medical care will
be billed to my insurance provider or me in the ordinary manner. I
understand that I will not be reimbursed for expenses or compensated
financially by M. D. Anderson for this injury. I may also contact the
Chair of M. D. Anderson’s IRB at 713-792-2933 with questions about
study-related injuries.
14. Certain tests, procedures, and/or medications that I may receive as
part of this study may be without cost to me because they are for
research purposes only. However, my insurance provider or I may be
financially responsible for the cost of supportive care and treatment of
any complications resulting from the research tests, procedures,
and/or medications, including hospitalization, nausea, vomiting, low
blood cell counts, and dehydration. Standard medical care that I
receive under this research study will be billed to my insurance
provider and/or me in the ordinary manner. I should learn before
taking part in this study which parts of the research-related care will
be provided without charge, which costs my insurance provider will
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pay for, and which costs will be my responsibility. I may ask to speak
with a financial counselor about the costs of this study.
15. I understand that there are no plans to compensate me for any
patents or discoveries that may result from my participation in this
research. I will receive no compensation for taking part in this study.
Authorization for Use and Disclosure of Protected Health
Information:
A. During the course of this study, the research team at M. D. Anderson
will be collecting information about you. This information may include
your medical history, study schedule, and the results of any of your
tests, therapies, and/or procedures. The purpose of collecting and
sharing this information is to learn about how the study procedures
may affect the disease and any study-related side effects. Your doctor
and the research team may share your study information with the
parties named in Section E below.
B. If you refuse to provide your authorization to disclose your protected
health information, you will not be able to participate in this research
study.
C. Your protected health information will be protected according to state
and federal law. However, there is no guarantee that your information
will remain confidential, and it may be re-disclosed at some point.
D. All identifying information such as your name and address will be kept
private. This information may be kept at M. D. Anderson forever. You
will be assigned a code number so that your name will not be used.
The research team at M. D. Anderson will be able to link the code
number to your name. In some instances, in order to ensure the
scientific value of the study, the parties named in Section E below will
be able to view your study record but will not be permitted to copy any
identifying information contained in your record.
E. Your information may be shared with the following parties:
The FDA
The OHRP
The IRB of M. D. Anderson
Officials of M. D. Anderson
Clinical study monitors who verify the accuracy of the
information
Individuals with medical backgrounds who determine the effect
that the study procedures may have on the disease
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Individuals who put all the study information together in report
form
F. You have the right to see and reproduce your records related to the
research study, and ask for corrections, for as long as this information
is held by the study chair and/or M. D. Anderson. However, in some
studies, in order to ensure the scientific value of the study,
participants are not able to view or reproduce their study records until
the research has been completed with all participants in the study. If
possible for this study, your doctor will be able to discuss your clinical
test results with you.
G. There is no expiration date for the use of your protected health
information. You may withdraw your authorization to share your
protected health information at any time in writing. Instructions on
how to do this can be found in the M. D. Anderson Notice of Privacy
Practices (NPP). You may contact the IRB Staff at 713-792-2933 with
questions about how to find the NPP. If you withdraw your
authorization, you will be removed from the study and the study chair
and staff will no longer use or disclose your protected health
information in connection with this study, unless the study chair or
staff needs to use or disclose some of your research-related protected
health information to preserve the scientific value of the study. The
parties listed in Section E above may use any study data that were
collected before you canceled your authorization.
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CONSENT/PERMISSION/AUTHORIZATION FOR TREATMENT
Having read and understood the above and having had the chance to ask
questions about this study, think about the study, and talk with others as
needed, I give the study chair permission to enroll me on this study. By
signing this consent form, I am not giving up any of my legal rights. I have
been given a signed copy of this consent document.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF PARTICIPANT
DATE

I was present during the explanation of the research to be performed
under Protocol 2009-0164.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF WITNESS TO THE VERBAL CONSENT
PRESENTATION (OTHER THAN PHYSICIAN OR STUDY CHAIR)

DATE

SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF PERSON RESPONSIBLE & RELATIONSHIP
DATE

I have discussed this clinical research study with the participant and/or his
or her authorized representative, using language that is understandable
and appropriate. I believe that I have fully informed this participant of the
nature of this study and its possible benefits and risks and that the
participant understood this explanation.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF STUDY CHAIR OR PERSON OBTAINING
CONSENT
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DATE

Translator
I have translated the above informed consent as written (without additions or
subtractions)
into _____________________________ and assisted the people
obtaining/providing
(Name of Language)
consent by translating all questions and responses during the consent
process for this participant.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
NAME OF TRANSLATOR

SIGNATURE OF TRANSLATOR DATE

Please check here if the translator was a member of the research
team. (If checked, a witness, other than the translator, must sign the
witness line.)
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C. Standard Operating Procedure

Standard Operating Procedure for
Vapotherm and Intermittent BiPap for Respiratory
Support in Patients with Advanced Neoplasm Trial
[VIBRANT Study]
Protocol 2009-0164

Table of Contents
STUDY CONTACTS ................................................................................................................................. 76
GENERAL INFORMATION AND STUDY FLOWCHART ................................................................ 77
ELIGIBILITY CRITERIA........................................................................................................................ 79
1)

PRE-SCREENING ........................................................................................................................... 80

2)

SCREENING..................................................................................................................................... 81

3)

ASSESSMENT #1 ............................................................................................................................. 82

4)

INTERVENTION #1 ........................................................................................................................ 83

5)

ASSESSMENT #2 ............................................................................................................................. 84

6)

WASHOUT PERIOD AND ASSESSMENT #3 ............................................................................. 85

7)

INTERVENTION #2 ........................................................................................................................ 86

8)

ASSESSMENT #4 ............................................................................................................................. 87

75

PRINCIPAL INVESTIGATOR: DR. EDUARDO BRUERA

Research Team Contacts
Research RN
Cheryl Scott
Pg: 606-3536
Ph: 745-1948

Research RT
Laura Withers
Pg: 404-1049
Ph: 745-7400

Research MD
David Hui
Pg: 606-3376
Ph: 745-7082

Second

Rachael Lane
Pg: 606-2296
Ph: 563-1859

Quan Nguyen
Pg: 606-5894
Ph: 563-6715

Sriram Yennu
Pg: 404-6350
Ph: 792-3938

Third

Brenda Coldman
Pg: 563-1685
Ph: 404-4509

Clarence Finch
Pg: 404-9418
Ph: 745-5475

Eduardo Bruera
Pg: 606-3633
Ph: 792-6084

Fourth

David Hui
Pg: 606-3376
Ph: 745-7082

First

Clinical RT Contacts (Pre-screen)
Jacob Kuruvila

Brandy Ward

James Cherian

Mathew
Asthappan

Jessica Schapper

Jessica Herbrich

Joe Blalack

Marion Bolden

Study Collaborators
Dr. Siriam Yennu
Dr. Ahmed Elsayem
Dr. Kristen Price
Dr. George Eapen
Dr. Saadia Faiz

76

General Information and Study Flowchart
•
•
•

Study runs Monday to Friday, 8am-5pm
Study interventions need to be initiated at or before noon
Any questions during this study should be directed to Dr. David Hui (6063376, dhui@mdanderson.org)
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Eligibility Criteria
Inclusion criteria:
1) Diagnosis of advanced cancer, defined as locally advanced, recurrent or
metastatic disease
2) Patients with persistent dyspnea, defined in this study as dyspnea at rest with
an average intensity level ≥3 out of a numeric rating scale from 0 to 10 for at
least 2 week and just prior to study initiation, despite supplemental oxygen of
up to 21 L/min to keep oxygen saturation ≥90%
3) Dyspnea is judged clinically to be predominantly due to underlying
malignancy, with or without obstructive lung disease
4) Inpatient at M.D. Anderson Cancer Center
5) On stable doses of opioids, steroids and bronchodilators, defined as no
significant change (±20%) in the total daily dose over the last 48 hours
6) Able to communicate in English
7) Expected life expectancy >1 week
8) Patients with a diagnosis of pneumonia are also eligible for this study if they
meet the eligibility criteria above, with dyspnea ≥2 weeks prior to the
diagnosis of pneumonia.
Exclusion criteria:
1) Patients who remain hypoxic (i.e. O2 saturation <90% despite maximal
oxygen delivery (21 L/min) are not included in this study because they are
considered to have severe life-threatening respiratory failure and are too
unstable for study inclusion.
2) Hemodynamic instability (HR >140, SBP <80) within 24 hours of study
initiation as per clinic station
3) Acute respiratory distress requiring intubation
4) Delirium as indicated by a Memorial Delirium Assessment Scale (MDAS) of
13 or higher
5) Glasglow coma scale <8
6) Excessive airway secretions interfering with BIPAP administration
7) History of facial trauma within 1 month of enrollment
8) Upper GI bleed within 2 weeks or esophageal rupture of enrollment
9) Partial or complete small bowel obstruction or severe nausea/vomiting (ESAS
nausea >7/10) within 48 hours of enrollment
10) Hemoglobin <8 g/dL at the time of enrollment (blood draw within last 2 weeks)
11) Acute exacerbation of COPD or CHF within 2 weeks of enrollment by history
or physical
12) Pulmonary embolus within 1 week of enrollment by history or physical
13) Unwilling to provide informed consent
14) Age 18 or under
15) Diagnosis of non-cancer related dyspnea (e.g. COPD, CHF or any chronic
respiratory disease) requiring supplemental home oxygen prior to
hospitalization.
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1) Pre-screening (Clinical RT/Research MD)
a) Clinical RTs (names and contact) in AM shift identifies potentially eligible
inpatients for dyspnea study:
i) Advanced cancer (metastatic or locally advanced)
ii) On supplemental oxygen and sat >90%
iii) Hemodynamically stable
iv) Likely able to tolerate BIPAP and Vapotherm
v) Alert and oriented
vi) “Do you have shortness of breath? If yes, for how long roughly?” If
the answer is for 2 weeks or longer, patients are potentially eligible for
study
b) If patient met above criteria, please discuss the following with the patient:
i) “We have a clinical trial to see if we can help improve your shortness of
breath. You get to try two different types of breathing machines for
about 2 hours each. I think it may be of interest to you. Would you like
to learn more about this study?”
ii) If yes, this patient is potentially eligible
c) Try to identify at least one potentially eligible patient per day per RT.
d) Clinical RTs page research MD on or before 10am, regardless of whether
you have a patient or not
i) If potentially eligible patient, provide the MRN, name and location for
any potentially eligible patients. This will be captured on a screening
log
ii) If no patients, please let research MD know as well
e) If research MD has not received any pages by 10am, will page the
research RTs to find out what happened.
f) If research MD not answering within 10 minutes, please page research
MD again. If still no answer within 5 minutes, page second research MD.
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2) Screening (Research MD/RN, estimate ~1 hour)
a) Research MD will review patient data (starting with the most likely
candidate) on Clinic Station to determine eligibility. If patient not
eligible on paper, research RN will inform patients.
b) If likely eligible, research MD will inform research RN do further prescreening on Clinic Station before going up to unit to approach patient
to
i) Discuss study protocol briefly, and ask for permission to screen
ii) Ask him/her about dyspnea rating over the last 2 weeks on
numeric rating scale (has to be ≥3/10)
iii) Ask him/her about dyspnea rating now on numeric rating scale
(has to be ≥3/10)
iv) Document the above in Appendix B
c) Research RN will complete rest of eligibility screening
i) If eligible, explain study in detail, provide consent form and ask if
patient agrees to participate. If yes, go to Section 2.c.iv. If no, go
to Section 2.c.i
ii) If not eligible or patient refused to participate, thank the patient and
inform RT patient not enrolled
iii) Document the above in Appendix B
iv) Ensure patient signed consent form
d) Determine if study can be started today
i) Research RN will check with patient first
ii) Research RN will notify the unit RN most responsible for the
patient’s care at the time that patient has agreed to participate in
this 5 hour study, and discuss the following:
(1) Whether there are any tests/procedures (if yes, whether they
can be rescheduled until after the study?)
(2) Patients who are already on scheduled opioids or steroids may
continue to receive them as per clinical care
(3) Patients who require any breakthrough opioids (parenteral,
oral, inhaled), breakthrough steroids (parenteral, oral or
inhaled) or scheduled/breakthrough bronchodilators will be
asked to hold the medications if possible. Otherwise, they will
need to come off study
iii) If patient okay and available, notify research MD so he will notify
attending physician of the study and obtain approval.
iv) Once all parties have agreed to proceed (patient, attending MD,
unit RN, research RN/MD), then proceed to Section 3
v) If not, determine if alternative time/day would work for him/her (note
that study should be started at or before noon). If patient cannot be
on study today, ask if he/she would be okay doing it tomorrow (start
at Section 2.b.iii again)
e) If multiple patients eligible on the same day, start study on one patient
first, and then return to the other patient the next day (start at Section
2.b.i).
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3) Assessment #1 – Baseline before intervention #1 (Research RN and
Research RT, estimate 30 minutes)
a) Page research RT
b) At the time when patient is ready to start the interventions, research
RN will print the study order form and include in chart.
c) Research RN will work with patient and family to complete the
assessment #1 study forms, and perform vitals assessments and
focused respiratory and cardiac examination
i) Appendix A - Patient Demographics and Baseline Characteristics
ii) Appendix C - Numeric Rating Scale for Study Assessments
iii) Appendix D - Modified Borg Scale for Study Assessments
iv) Appendix E - Cancer Dyspnoea Scale
v) Appendix J - Patient Reported Adverse Effect Form
d) Research RN will provide research RT with randomization code to
decide which intervention would be started first.
e) Research RT will perform the following
i) Get equipments organized
ii) Explain to patient how the interventions work
iii) Answer any questions and provide reassurance
iv) Complete assessment #1 Appendix L- Data Collection for
Respiratory Settings
v) Set recording trend (30, 60, 90 and 120min) for vitals assessment
(HR, RR, BP), TCO2 and oximetry reading
vi) Once patient and research RN all ready, start intervention #1 using
the following parameters
Vapotherm:
Device: Vapotherm 2000i Respiratory Therapy Device
FiO2: set at 100%
Heat: between 35° and 37°
Oxygen flow: titrate between 10 L/min and 40 L/min to achieve
the highest oxygen flow to minimize dyspnea while keeping the
patient comfortable
BIPAP:
Device: The BIPAP Vision Ventilatory Support System
Mask: choice of nasal or face mask
Mode: pressure support mode (S/T)
FiO2: set at 100%
IPAP and EPAP: started at an inspiratory pressure of 8 cm of
H2O and expiratory pressure of 5 cm of H2O. Titrate to minimize
dyspnea and discomfort. Target inspiratory pressure between 8
and 18 cm of H2O, and target expiratory pressure between 3
and 10 cm of H2O

82

4) Intervention #1 (Research RN and Research RT, estimate 2 hours)
a) Once patient on stable respiratory setting, research RT will leave and
plan to return approximately 10 minutes before termination of
intervention #1. During this time, research RT will be available by
pager.
b) Research RN may also leave after completion of assessment #1 after
notifying unit nurses to keep an eye on patient and to page her/RT if
needed.
c) Research RN will return after 1 hour of intervention (±10 minutes) to
see how the patient is doing. If patient in distress, notify RT.
Otherwise, leave and return approximately 10 minutes before
termination of intervention #1.
d) Anytime during the study, patients who could not tolerate an
intervention because of discomfort will be offered the opportunity to
i) Temporarily halt the intervention (back to supplemental O2) and
resume when ready. Research RT will be paged ASAP, complete
appendix L.
ii) Switch to alternative intervention after a variable washout period (if
only tried first intervention – go to section 4. Research RN will
complete Appendix K and research RT will complete Appendix L).
OR
iii) Discontinue the study and go back to supplemental O2. Research
RT will be paged ASAP. Research RN will complete Appendix K
and research RT will complete Appendix L.
e) If patients require any breakthrough opioids (parenteral, oral,
inhaled), breakthrough steroids (parenteral, oral or inhaled) or
scheduled/breakthrough bronchodilators, they will need to come off
study. Research RN and research RT will be paged by unit RN, fill out
Appendix K and L, respectively.
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5) Assessment #2 (Research RN and Research RT, estimate 10 minutes)
a) Both research RN and research RT will return approximately 10
minutes before conclusion of intervention #1. If one or the other not
available, page each other ASAP (or their backups).
b) During the next 5-10 minutes, research RN will work with patient and
family to complete the assessment #2 study forms before research RT
stops intervention #1.
i) Appendix C - Numeric Rating Scale for Study Assessments
ii) Appendix D - Modified Borg Scale for Study Assessments
iii) Appendix F - Global Symptom Evaluation
iv) Appendix J - Patient Reported Adverse Effect Form
v) Appendix K - Data Collection for Assessments
c) Research RT will complete assessment #2 Appendix L - Data
Collection for Respiratory Settings
d) Upon completion of all assessments, research RT will stop intervention
#1 and put patient back on baseline intervention (same as prior to
study).
e) Go to washout period (Section 6).
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6) Washout period and assessment #3 (Research RN and Research RT,
estimate 10 minutes to 1 hour)
a) Research RT may leave if patient stable, but will be paged back if and
when patient ready to start intervention #2.
b) Research RN will check if patient returns to close to baseline level of
dyspnea using Appendix I every 10 minutes (e.g. if patient’s baseline
dyspnea is 5, then he/she has to be at least 4 or above to start next
intervention).
c) Once patient is ready for next intervention, research RN will page
research RT back ASAP.
d) In the meantime, research RN will complete assessment #3 with
patient
i) Appendix C - Numeric Rating Scale for Study Assessments
ii) Appendix D - Modified Borg Scale for Study Assessments
iii) Appendix J - Patient Reported Adverse Effect Form
e) Research RT will perform the following:
i) Get equipments organized
ii) Explain to patient how the interventions work
iii) Answer any questions and provide reassurance
iv) Complete assessment #3 Appendix L- Data Collection for
Respiratory Settings
v) Set recording trend (30, 60, 90 and 120min) for vitals assessment
(HR, RR, BP), TCO2 and oximetry reading
vi) Once patient and research RN all ready, start intervention #2 using
the following parameters
Vapotherm:
Device: Vapotherm 2000i Respiratory Therapy Device
FiO2: set at 100%
Heat: between 35° and 37°
Oxygen flow: titrate between 10 L/min and 40 L/min to achieve
the highest oxygen flow to minimize dyspnea while keeping the
patient comfortable
BIPAP:
Device: The BIPAP Vision Ventilatory Support System
Mask: choice of nasal or face mask
Mode: pressure support mode (S/T)
FiO2: set at 100%
IPAP and EPAP: started at an inspiratory pressure of 8 cm of
H2O and expiratory pressure of 5 cm of H2O. Titrate to minimize
dyspnea and discomfort. Target inspiratory pressure between 8
and 18 cm of H2O, and target expiratory pressure between 3
and 10 cm of H2O
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7) Intervention #2 (Research RN and Research RT, estimate 2 hours)
a) Once patient on stable respiratory setting, research RT will leave and
plan to return approximately 15 minutes before termination of
intervention #2. During this time, research RT will be available by
pager.
b) Research RN may also leave after completion of assessment #2, and
notify unit nurses to keep an eye on patient, then page her/RT if
needed.
c) Research RN will return after 1 hour of intervention (±10 minutes) to
see how the patient is doing. If patient in distress, notify RT.
Otherwise, leave and return approximately 15 minutes before
termination of intervention #2.
d) Anytime during the study, patients who could not tolerate an
intervention because of discomfort will be offered the opportunity to
i) Temporarily halt the intervention (back to supplemental O2) and
resume when ready. Research RT will be paged ASAP, complete
appendix L.
ii) Discontinue the study and go back to supplemental O2. Research
RT will be paged ASAP. Research RN will complete Appendix K
and research RT will complete Appendix L.
e) If patients require any breakthrough opioids (parenteral, oral,
inhaled), breakthrough steroids (parenteral, oral or inhaled) or
scheduled/breakthrough bronchodilators, they will l need to come off
study. Research RN and Research RT will be paged, fill out Appendix
K and L, respectively.
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8) Assessment #4 (Research RN and Research RT, estimate 15 minutes)
a) Both research RN and research RT will return approximately 15
minutes before conclusion of intervention #2. If one or the other not
available, page each other ASAP (or their backups).
b) During the next 10 minutes, research RN will work with patient and
family to complete the assessment #4 study forms before research RT
stops intervention #2.
i) Appendix C - Numeric Rating Scale for Study Assessments
ii) Appendix D - Modified Borg Scale for Study Assessments
iii) Appendix G - Global Symptom Evaluation and Study Evaluation
iv) Appendix H - Patient Preference Survey (done after patient back
on supplemental oxygen)
v) Appendix J - Patient Reported Adverse Effect Form
c) Research RT will complete assessment #4 Appendix L - Data
Collection for Respiratory Settings
d) Upon completion of all assessments, research RT will stop intervention
#2 and put patient back on baseline intervention (same as prior to
study).
e) Study completed. Research RN and research RT sign over the clinical
RT. No further followup. Resume all medications as per prior to study.
f) Thank patient, unit RN and clinical RT
g) Patient has the opportunity to return to baseline oxygen delivery, or
use BiPAP or Vapotherm if agreed by with attending team
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D. Study Budget
BUDGET
Year 1

A. Personnel
(Indicate percent effort, salary, and names
of personnel)
Respiratory therapists
Research RN
Data coordinator
Fringe Benefits Total

Year 2

$0 (dept)
$0 (dept
$0 (dept
$0

Category Total
B. Permanent Equipment (Itemize)
Sentec Digital Monitoring System

$9,700.00

Category Total
C. Supplies (Group into major
categories)
CPAP Mask (50 units)

$9,700.00

$1550.00

CPAP tubing (50 units)

$485.00

O2 filter (50 units)

$101.00

Vaportherm Filter & Setup (50 units)
Sentec Digital Monitoring System supplies
(50 units)
Category Total
D. Travel (DoD. Travel (Domestic only)

$6,745.00
$3180.00
$12655.00

Category Total
E. Miscellaneous
(List specific amounts for each item)

$0

Category Total

$0

F. SUBCONTRACTS (CATEGORIZE ON
CONTINUATION PAGE)
Category Total
$21761.00
$0

Total Direct Costs
G. Indirect Costs:
%) (Excluding
permanent equipment)
Total Indirect Costs
TOTAL ANNUAL COSTS
H. Total Amount Requested

$21761.00

(Sum of all years including indirect
costs; transfer this amount to the budget
section of the on-line form)
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